Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic.
Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, Hanna G, Jagsi R, Kaidar Person O, Kirby A, Mjaaland I, Meattini I, Luis AM, Marta GN, Offersen B, Poortmans P, Rivera S. Coles CE, et al. Among authors: offersen b. Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281. doi: 10.1016/j.clon.2020.03.006. Clin Oncol (R Coll Radiol). 2020. PMID: 32241520 Free PMC article. No abstract available.
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Rydén L, Olofsson Bagge R, Sund M, Johansson H, Lundstedt D; SENOMAC Trialists’ Group. de Boniface J, et al. BMC Cancer. 2017 May 26;17(1):379. doi: 10.1186/s12885-017-3361-y. BMC Cancer. 2017. PMID: 28549453 Free PMC article. Clinical Trial.
The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
de Boniface J, Ahlgren J, Andersson Y, Bergkvist L, Frisell J, Lundstedt D, Olofsson Bagge R, Rydén L, Sund M; SENOMAC Trialists’ Group. de Boniface J, et al. Breast Cancer Res Treat. 2020 Feb;180(1):167-176. doi: 10.1007/s10549-020-05537-1. Epub 2020 Jan 27. Breast Cancer Res Treat. 2020. PMID: 31989379 Free PMC article.
Radiotherapy for breast cancer, the TARGIT-A trial.
Yarnold J, Offersen BV, Olivotto I, Poortmans P, Sarin R. Yarnold J, et al. Lancet. 2014 May 17;383(9930):1717-8. doi: 10.1016/S0140-6736(14)60828-X. Lancet. 2014. PMID: 24835611 No abstract available.
Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time?
Kaidar-Person O, Poortmans P, Klimberg S, Haviland J, Offersen B, Audisio R, Yarnold J. Kaidar-Person O, et al. Among authors: offersen b. Breast Cancer Res Treat. 2014 Aug;147(1):221-2. doi: 10.1007/s10549-014-3032-5. Epub 2014 Jul 22. Breast Cancer Res Treat. 2014. PMID: 25048466 No abstract available.
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer.
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. Offersen BV, et al. Radiother Oncol. 2015 Jan;114(1):3-10. doi: 10.1016/j.radonc.2014.11.030. Epub 2015 Jan 24. Radiother Oncol. 2015. PMID: 25630428
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D, Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso MJ, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E, Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove C, MacGrogan G, Michiels S, Negreiros I, Offersen BV, Penault Llorca F, Pruneri G, Roche H, Russell NS, Schmitt F, Servent V, Thürlimann B, Untch M, van der Hage JA, van Tienhoven G, Wildiers H, Yarnold J, Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli TS. Gourgou-Bourgade S, et al. Among authors: offersen bv. Ann Oncol. 2015 May;26(5):873-879. doi: 10.1093/annonc/mdv106. Epub 2015 Feb 27. Ann Oncol. 2015. PMID: 25725046 Free article. Review.
ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1.
Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Sola AB, Kirova YM, Pignol JP, Remouchamps V, Verhoeven K, Weltens C, Arenas M, Gabrys D, Kopek N, Krause M, Lundstedt D, Marinko T, Montero A, Yarnold J, Poortmans P. Offersen BV, et al. Radiother Oncol. 2016 Jan;118(1):205-8. doi: 10.1016/j.radonc.2015.12.027. Epub 2016 Jan 18. Radiother Oncol. 2016. PMID: 26791404 No abstract available.
The 2016 Assisi Think Tank Meeting on breast cancer: white paper.
Aristei C, Kaidar-Person O, Arenas M, Coles C, Offersen BV, Bourgier C, Frezza G, Leonardi MC, Valentini V, Poortmans PM. Aristei C, et al. Breast Cancer Res Treat. 2016 Nov;160(2):211-221. doi: 10.1007/s10549-016-3998-2. Epub 2016 Sep 29. Breast Cancer Res Treat. 2016. PMID: 27686462
141 results